Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Obstet Gynecol. 2018 Sep;132(3):545–554. doi: 10.1097/AOG.0000000000002796

Figure 2.

Figure 2

Progression-free survival in patients undergoing laparoscopic scoring assessment by treatment group (A). Median progression-free survival was 21.4 months for primary surgery compared to 12.9 months for the NACT group (P<.001). Progression-free survival in patients undergoing laparoscopic scoring assessment by residual disease and treatment group (B). Median progression-free survival was 23.5 months for primary surgery–R0, 17.6 months for primary surgery–R1, 15.5 months for NACT–R0, and 12.9 months for NACT–R1 (P<.001). NACT, neoadjuvant chemotherapy; R0, no gross residual disease; R1, any gross residual disease remaining (≤1 cm or >1 cm). Numbers in parentheses represent the number of events (deaths or progressions) between the two time points.